The Journal of Organic Chemistry
Note
as a white solid (80 mg, 89%). Mp: 171−172 °C. 1H NMR δ: 7.92 (d,
J = 8.4 Hz, 2H); 7.56 (d, J = 8.4 Hz, 2H); 7.36 (d, J = 8.7 Hz, 4H);
7.06 (d, J = 8.7 Hz, 4H); 3.91 (s, 6H); 2.91 (t, J = 7.2 Hz, 4H); 1.78−
1.67 (m, 4H); 1.42−1.18 (m, 4H); 0.86 (t, J = 7.2 Hz, 6H) ppm. 13C
NMR δ: 158.9; 141.1; 137.7; 136.2; 134.7; 131.2; 127.9; 125.7; 121.8;
120.8; 114.0; 55.3; 34.1; 25.6; 22.3; 13.8 ppm. MS m/z (int rel) 564
(100 M•+); 521 (43); 464 (28). Anal. Calcd for C36H36O2S2: C, 76.56;
H, 6.42. Found: C, 76,39, H, 6.63. X-ray: triclinic, space group P-1, a =
10.689(1) Å, b = 14.404(1) Å, c = 19.076(1) Å, α = 98.344(3)°, β =
90.870(3)°, γ = 91.061(3)°, V = 2905.0(4) Å3, Z = 2, Dc = 1.291, μ =
1.901 mm−1, F(000) = 1200. 23272 reflections were collected with a
4.14 < θ < 70.66 range with a completeness to θ 95.3%; 10632 were
unique, the parameters were 721 and the final R index was 0.0505 for
reflections having I > 2σI and 0.0757 for all data. The asymmetric unit
contains two independent molecules as they are not equivalent from a
crystallographic point of view. It is mainly due to the different torsion
angles between sulfur atoms and the alkylic chains. No significant
intra- or intermolecular interactions can be detected.
(5) As angiogenesis inhibitors: (a) Boschelli, D. H.; Kramer, J. B.;
Connor, D. T.; Lesch, M. E.; Schrier, D. J.; Ferin, M. A.; Wright, C. D.
J. Med. Chem. 1994, 37, 717−718. (b) Cobb, R. R.; Felts, K. A.;
McKenzie, T. C.; Parry, G. C. N.; Mackman, N. FEBS Lett. 1996, 382,
323−326. (c) Gualberto, A.; Marquez, G.; Garballo, M.; Youngblood,
G. L.; Hunt, S. W.; Baldwin, A. S.; Sobrino, F. J. Biol. Chem. 1998, 273,
7088−7093.
(6) As site-directed thrombin inhibitors: (a) Sall, D. J.; Bastian, J. A.;
Briggs, S. L.; Buben, J. A.; Chirgadze, N. Y.; Clawson, D. K.; Denney,
M. L.; Giera, D. D.; Gifford-Moore, D. S.; Harper, R. W.; Hauser, K.
L.; Klimkowski, V. J.; Kohn, T. J.; Lin, H.; McCowan, J. R.; Palkowitz,
A. D.; Smith, G. F.; Takeuchi, K.; Thrasher, K. J.; Tinsley, J. M.;
Utterback, B. G.; Yan, S. B.; Zhang, M. J. Med. Chem. 1997, 40, 3489−
3493. (b) Takeuchi, K.; Kohn, T. J.; Bastian, J. A.; Chirgadze, N. Y.;
Denney, M. L.; Harper, R. W.; Lin, H.; Mccowan, J. R.; Gifford-
Moore, D. S.; Richett, M. E.; Sall, D. J.; Smith, G. F.; Zhang, M. Bioorg.
Med. Chem. Lett. 1999, 9, 759−764.
(7) As anti-inflammatory agents: (a) Wright, C. D.; Stewart, S. F.;
Kuipers, P. J.; Hoffman, M. D.; Devall, L. J.; Kennedy, J. A.; Ferin, M.
A.; Theuson, D. O.; Conroy, M. C. J. Leukocyte Biol. 1994, 55, 443−
451. (b) Bleavins, M. R.; de La Igelsia, F. A.; McCay, J. A.; White, L.,
Jr.; Kimber, L.; Munson, A. E. Toxicology 1995, 98, 111−123.
(8) (a) Anthony, J. E. Chem. Rev. 2006, 106, 5028−5048.
(b) Anthony, J. E. Angew. Chem., Int. Ed. 2008, 47, 452−483.
(c) Liu, Y.; Di, C-a.; Du, C.; Liu, Y.; Lu, K.; Qiu, W.; Yu, G. Chem.
Eur. J. 2010, 16, 2231−2239. (d) Takimiya, K.; Shinamura, S.; Osaka,
I.; Miyazaki, E. Adv. Mater. 2011, 23, 4347−4370.
(9) (a) Shinamura, S.; Miyazaki, E.; Kazuo Takimiya, K. J. Org. Chem.
2010, 75, 1228−1234. (b) Shinamura, S.; Osaka, I.; Miyazaki, E.;
Nakao, A.; Yamagishi, M.; Takeya, J.; Takimiya, K. J. Am. Chem. Soc.
2011, 133, 5024−5035. (c) Loser, S.; Bruns, C. J.; Miyauchi, H.; Ortiz,
R. P.; Facchetti, A.; Stupp, S. I.; Marks, T. J. J. Am. Chem. Soc. 2011,
133, 8142−8145. (d) Shinamura, S.; Sugimoto, R.; Yanai, N.;
Takemura, N.; Kashiki, T.; Osaka, I.; Miyazaki, E.; Takimiya, K. Org.
Lett. 2012, 14, 4718−4721. (e) Sanjaykumar, S. R.; Badgujar, S.; Song,
C. E.; Shin, W. S.; Moon, S.-J.; Kang, I.-N.; Lee, J.; Cho, S.; Lee, S. K.;
Lee, J.-C. Macromolecules 2012, 45, 6938−6945. (f) Loser, S.;
Miyauchi, H.; Hennek, J. W.; Smith, J.; Huang, C.; Facchetti, A.;
Marks, T. J. Chem. Commun. 2012, 48, 8511−8513.
ASSOCIATED CONTENT
* Supporting Information
■
S
Copies of 1H and 13C NMR spectra of compounds 7−18; CIF
files and ORTEP diagrams of compounds 12, 14, 15, 17, and
18; UV−vis spectra and cyclic voltammograms of compounds
12−14, 17, and 18; HOMO−LUMO orbitals, atom
coordinates, and absolute energies of compounds 12, 14, 17,
and 18. This material is available free of charge via the Internet
AUTHOR INFORMATION
Corresponding Author
■
Notes
The authors declare no competing financial interest.
ACKNOWLEDGMENTS
■
Work carried out in the framework of MIUR PRIN2010-2011
project “PROxi” cod. 2010PFLRJR_007.
(10) (a) Yue, D.; Larock, R. C. J. Org. Chem. 2002, 67, 1905−1909.
(b) Nakamura, I.; Sato, T.; Yamamoto, Y. Angew. Chem., Int. Ed. 2006,
45, 4473−4475. (c) Jeong, J. H.; Yoon, U. Y.; Jang, S. H.; Yoo, U.-A.;
Kim, S. N.; Truong, B. T.; Shin, S. C.; Yoon, Y.-J.; Singh, O. M.; Lee,
S.-G. Synlett 2007, 1407−1410. (d) Matsnev, A.; Noritake, S.;
Nomura, Y.; Tokunaga, E.; Nakamura, S.; Norio Shibata, N. Angew.
Chem., Int. Ed. 2010, 49, 572−576. (e) Jacubert, M.; Tikad, A.; Provot,
O.; Hamze, A.; Brion, J.-D.; Alami, M. Eur. J. Org. Chem. 2010, 4492−
4500.
DEDICATION
■
This paper is dedicated to the memory of Prof. Alessandro
Degl’Innocenti.
REFERENCES
■
(11) (a) Kashiki, T.; Shinamura, S.; Kohara, M.; Miyazaki, E.;
Takimiya, K.; Ikeda, M.; Kuwabara, H. Org. Lett. 2009, 11, 2473−2475.
(b) Sun, L.-L.; Deng, C.-L.; Tang, R.-Y.; Zhang, X.-G. J. Org. Chem.
2011, 76, 7546−7550.
(1) Jones, C. D.; Jevnikar, M. G.; Pike, A. J.; Peters, M. K.; Black, L.
J.; Thompson, A. R.; Falcone, J. F.; Clemens, J. A. J. Med. Chem. 1984,
27, 1057−1066.
(2) (a) Magarian, R. A.; Overacre, L. B.; Singh, S.; Meyer, K. L. Curr.
Med. Chem. 1994, 1, 61−86. (b) Palkowitz, A. D.; Glasebrook, A. L.;
Thrasher, K. J.; Hauser, K. L.; Short, L. L.; Phillips, D. L.; Muehl, B. S.;
Sato, M.; Shetler, P. K.; Cullinan, G. J.; Pell, T. R.; Bryant, H. U. J.
Med. Chem. 1997, 40, 1407−1416. (c) Chen, Z.; Mocharla, V. P.;
Farmer, J. M.; Pettit, G. R.; Hamel, E.; Pinney, K. G. J. Org. Chem.
2000, 65, 8811−8815. (d) Schopfer, U.; Schoeffter, P.; Bischoff, S. F.;
Nozulak, J.; Feuerbach, D.; Floersheim, P. J. Med. Chem. 2002, 45,
1399−1401. (e) Liu, H.; Liu, J.; van Breemen, R. B.; Thatcher, G. R. J.;
Bolton, J. L. Chem. Res. Toxicol. 2005, 18, 162−173.
(12) Capozzi, G.; De Sio, F.; Nativi, C.; Menichetti, S.; Pacini, P. L.
Synthesis 1994, 521−525.
(13) Capozzi, G.; Gori, L.; Menichetti, S.; Nativi, C. J. Chem. Soc.,
Perkin Trans. 1 1992, 1923−1928.
(14) Lamanna, G.; Menichetti, S. Adv. Synth. Catal. 2007, 349, 2188−
2194.
(15) Lamanna, G.; Faggi, C.; Gasparrini, F.; Ciogli, A.; Villani, C.;
Stephens, J. P.; Devlin, J. F.; Menichetti, S. Chem.Eur. J. 2008, 14,
5747−5750.
(16) While amides are commonly protonated at carboxylic oxygen,
sulfenamides are protonated at nitrogen: Bagno, A.; Eustace, S. J.;
Johansson, L.; Scorrano, G. J. Org. Chem. 1994, 59, 232−233.
(17) It is worth mentioning that no preference for protic vs Lewis
acids is observed when arylthiophthalimides are used as sulfur transfer
reagents in intermolecular SEAr with indoles and pyrroles: Marcantoni,
E.; Cipolletti, R.; Marsili, L.; Menichetti, S.; Properzi, R.; Viglianisi, C.
Eur. J. Org. Chem. 2013, 132−140.
(3) As tubulin-binding agents: (a) Zhang, S.-X.; Bastow, K. F.;
Tachibana, Y.; Kuo, S.-C.; Hamel, E.; Mauger, A.; Narayanan, V. L.;
Lee, K.-H. J. Med. Chem. 1999, 42, 4081−4087. (b) Flynn, B. L.;
Verdier-Pinard, P.; Hamel, E. Org. Lett. 2001, 3, 651−654.
(4) As modulators of multidrug resistance: Norman, B. H.; Dantzig,
A. H.; Kroin, J. S.; Law, K. L.; Tabas, L. B.; Shepard, R. L.; Palkowitz,
A. D.; Hauser, K. L.; Winter, M. A.; Sluka, J. P.; Starling, J. J. Bioorg.
Med. Chem. Lett. 1999, 9, 3381−3386.
F
dx.doi.org/10.1021/jo400205j | J. Org. Chem. XXXX, XXX, XXX−XXX